TP53 and breast cancer: While rare protein-truncating and missense mutations in TP53 have been shown to exhibit moderate to high penetrance for both ER + and ER- breast cancer, they have only been implicated in prior GWAS but not TWAS studies of breast cancer [14, 38, 61, 63].